Results 171 to 180 of about 151,566 (299)

Carbon Monoxide Poisoning Presenting With Transient Visual Field Defects. [PDF]

Cureus
Chilukuri SNS, Krishnappa H.
europepmc   +1 more source

CARBON MONOXIDE AND OZONE [PDF]

American Journal of Public Health, 1927
openaire   +2 more sources

Thermal Calculations for Co‐Firing of Hydrogen/Ammonia and Coal in 660‐MW Coal‐Fired Boilers

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT To achieve a clean energy transition under the dual carbon goals, blending hydrogen/ammonia into pulverized coal boilers represents a key technological pathway. Different hydrogen/ammonia co‐firing ratios (5%–50%) are investigated for their impact on the thermodynamic characteristics of 660‐MW supercritical boiler at 100% and 20% boiler ...
Yaodong Da, Nana Hou, Weipeng Wang, Yongqiang Chang, Xin Liu, Feng Pan, Defu Che, Lei Deng   +7 more
wiley   +1 more source

Genomic Survey of Carbon Monoxide Dehydrogenases Reveals Their Widespread Distribution in Marine Habitats. [PDF]

Environ Microbiol Rep
Chongdar N, Goyal A, Damare SR.
europepmc   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

Arthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Predictors of Abnormal Diffusing Capacity for Carbon Monoxide in Post-pneumonia Ugandans With and Without HIV. [PDF]

J Acquir Immune Defic Syndr
Byanova KL, Fitzpatrick J, Zawedde J, Byanyima P, Sanyu I, Zhang MH, Branchini J, Velasquez E, Abelman R, Sessolo A, Lin J, North CM, Lalitha R, Bhakta NR, Hunt PW, Worodria W, Huang L.   +16 more
europepmc   +1 more source

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia, Marusa Kotnik, Timothy J. Sadler, Spyridon Katechis, Rachel Jones, Ajay Kamath, Aladdin J. Mohammad, Sara Monti, Chetan Mukhtyar, Viral Nanda, Ioannis Petrakis, Dimitrios Petras, Ashnish Sinha, Pasupathy Sivasothy, Rona Smith, Kostas Stylianou, Dimitrios Vassilopoulos, Judith Babar, David Jayne   +18 more
wiley   +1 more source

A Cu(II)-Based Fluorescent Probe for Carbon Monoxide, Nap-BC-Cu(II), Does Not Selectively Detect Carbon Monoxide. [PDF]

Molecules
Liu D, Li H, Challa S, Wang B.
europepmc   +1 more source

Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) is an important extra‐articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung ...
Marie Vermant, Valerie Van Ballaer, Joseph Jacob, Tine Follet, Ryoko Egashira, Kenny Anseele, Heleen Cypers, Laurens J. De Sadeleer, Nico De Crem, Tinne Goos, Barbara Neerinckx, Veerle Taelman, Nathalie Veyt, Alexandros Kalkanis, Patrick Verschueren, Wim A. Wuyts   +15 more
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source